# Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

> **NCT01026051** · PHASE2 · TERMINATED · sponsor: **Mannkind Corporation** · enrollment: 5 (actual)

## Conditions studied

- Stage III Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** MKC1106-MT

## Key facts

- **NCT ID:** NCT01026051
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-09
- **Final completion:** 2012-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Financial/Business Reasons
- **Last updated:** 2012-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026051, "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01026051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*